What Are the Side Effects of Tirzepatide — and How Do You Manage Them?

The first injection arrives, and your stomach has opinions

Most people starting tirzepatide describe the first few weeks as a negotiation with their digestive system. You eat less than you expected, feel full after a small meal, and somewhere in the background your gut is adjusting to a medicine that slows gastric emptying, the rate at which food leaves the stomach. That slowing is part of how tirzepatide reduces appetite; it is also the reason nausea is so common early on.

The NHS medicines page for tirzepatide lists nausea, vomiting, diarrhoea, constipation, stomach discomfort, indigestion, acid reflux and burping as common reactions. Fatigue, headache and dizziness appear on that list too, and injection-site reactions (redness, mild swelling) are possible wherever you rotate the pen. None of this is unusual or a sign that something has gone wrong. For many people the symptoms are at their most noticeable with the 2.5 mg starting dose and after each step up, then settle within days to roughly two weeks.

Practical things that help: small, low-fat meals; staying well hydrated; eating slowly; avoiding rich or heavily spiced food in the first days after each new dose. You can read more about what side effects Mounjaro causes and how people generally navigate them. If your symptoms feel unmanageable, contact your prescriber before adjusting anything yourself; our prescribers are available seven days a week for exactly these conversations.

Side effects that need a closer look, not panic, but attention

Beyond the GI symptoms, a smaller number of reactions deserve more than watchful waiting. Gallbladder problems (including gallstones) have been reported with tirzepatide; persistent upper-right abdominal pain or pain spreading to the shoulder blade is worth a prompt call to your GP or 111. Rapid weight loss of any kind can raise the risk of gallstones forming, so this is a category to be aware of even if the absolute risk is low.

Heart-rate increases have been noted in clinical data. If you feel an unusually fast or pounding heartbeat that is new and persists, mention it to a clinician. Mood changes (low mood, anxiety, changes in how you feel about yourself) are worth raising too; our page on tirzepatide's effects on mood covers what the evidence currently shows.

Dehydration is an underestimated risk. If vomiting or diarrhoea is severe enough to prevent you keeping fluids down, that can stress the kidneys, described in the literature as acute kidney injury secondary to volume depletion. The message is straightforward: if you cannot stay hydrated because of GI side effects, seek medical advice that day. This is one of the questions our clinical FAQs address if you want to check the threshold for calling.

When to get medical help without delay

There are specific symptoms where the right action is to stop treatment and get help immediately, not to wait and see how things develop. The MHRA's January 2026 Drug Safety Update on GLP-1 receptor agonists (including tirzepatide) draws particular attention to acute pancreatitis. The warning sign is severe, persistent pain in the abdomen that radiates into the back, sometimes accompanied by vomiting. If you experience this, stop your injection and seek urgent care; do not resume treatment without clinical guidance.

Other situations that require prompt medical attention: signs of a serious allergic reaction (swollen face, lips or throat; difficulty breathing; widespread rash); yellowing of the skin or eyes suggesting liver involvement; sudden or worsening vision changes (relevant for anyone with a history of diabetic retinopathy); thoughts of self-harm or significant changes in mental state. This list is not exhaustive, your Patient Information Leaflet, which comes with every pen, sets out the complete picture. Always keep it to hand, especially in the first months of treatment.

One practical tip a lot of patients find useful: photograph your leaflet or save the NHS tirzepatide page on your phone so you are not searching for it at 11pm on a Thursday. For a fuller rundown of the specific reactions reported across the clinical programme, our guide to side effects from tirzepatide goes further into what the data shows. If you want to explore whether tirzepatide is appropriate for your circumstances, our prescribers discuss suitability and side effects thoroughly as part of the free consultation, check your eligibility here.

How the risk picture fits into the wider evidence

Tirzepatide is a dual GIP and GLP-1 receptor agonist, the only medicine of its type licensed in the UK for weight management. It carries the MHRA's Black Triangle designation, which means it is under intensified surveillance while longer-term safety data accumulates from real-world use. That is a standard designation for recently approved medicines, not a signal of unusual danger, but it does mean the evidence base is still growing and prescribers follow it closely.

The side-effect profile seen in clinical trials (particularly SURMOUNT-1, involving over 2,500 participants) was broadly consistent with what clinicians expected from the GLP-1 mechanism, plus some additional GIP-related effects. Serious adverse events were infrequent, and the rates of discontinuation due to side effects were meaningful but not the majority experience. If you are weighing up your options, our detailed page on tirzepatide side effects gives a clear, plain-English breakdown that many people find helpful at this stage.

If you are also taking oral contraceptives, there is one interaction worth knowing: for the first four weeks of treatment and for four weeks after each dose increase, additional contraception is advisable because tirzepatide may reduce pill absorption. NHS England's guidance on weight-management injections sets this out clearly. For a broader view of who tirzepatide is licensed for and how the treatment works day to day, the Mounjaro overview is the natural next read.